Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model - Wikidata - awgldk - TriplyDB

Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model

Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model

http://www.wikidata.org/entity/Q35104249

about

Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease The role of tau in neurodegenerative diseases and its potential as a therapeutic target Prion-like properties of Tau protein: the importance of extracellular Tau as a therapeutic target Tau-targeted treatment strategies in Alzheimer's disease Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models Human wild-type full-length tau accumulation disrupts mitochondrial dynamics and the functions via increasing mitofusins.Sex and Immunogen-Specific Benefits of Immunotherapy Targeting Islet Amyloid Polypeptide in Transgenic and Wild-Type Mice Inflammatory process in Alzheimer's Disease Tau Biology and Tau-Directed Therapies for Alzheimer's Disease Friend or foe: the dichotomous impact of T cells on neuro-de/re-generation during aging Immunotherapeutic approaches for Alzheimer's disease The Role of MAPT in Neurodegenerative Diseases: Genetics, Mechanisms and Therapy Allostery in the Hsp70 chaperone proteins Curcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic mice Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies Affinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy.Propagation of tau pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies.Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg-AD mice Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice.Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis.Novel immunological approaches for the treatment of Alzheimer's disease.Antibody-derived in vivo imaging of tau pathology.Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice.Tau aggregation and its interplay with amyloid-β.Inhibition of tau aggregation by a rosamine derivative that blocks tau intermolecular disulfide cross-linking.Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice.The toxicity of tau in Alzheimer disease: turnover, targets and potential therapeutics p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice.ENU mutagenesis screen to establish motor phenotypes in wild-type mice and modifiers of a pre-existing motor phenotype in tau mutant mice.Encapsulated cellular implants for recombinant protein delivery and therapeutic modulation of the immune system.Passive Immunization in JNPL3 Transgenic Mice Using an Array of Phospho-Tau Specific Antibodies.Doubly Phosphorylated Peptide Vaccines to Protect Transgenic P301S Mice against Alzheimer's Disease Like Tau Aggregation.Stabilization of Microtubule-Unbound Tau via Tau Phosphorylation at Ser262/356 by Par-1/MARK Contributes to Augmentation of AD-Related Phosphorylation and Aβ42-Induced Tau Toxicity.Humanized Tau Mice with Regionalized Amyloid Exhibit Behavioral Deficits but No Pathological Interaction.Trans-cellular propagation of Tau aggregation by fibrillar species Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain.A fresh perspective from immunologists and vaccine researchers: active vaccination strategies to prevent and reverse Alzheimer's disease.Soluble forms of tau are toxic in Alzheimer's disease.

P2860

Q26739412-B76EC32A-6E9D-4B18-9F45-63737960412E Q27005032-76EE0A59-1F81-4F1D-A807-0E26E59A8CA0 Q27021159-F8957EDB-6651-4C3D-8EB6-02563B818906 Q27023429-318AA5C1-6590-4434-8DB0-9EF7ED1F32FB Q27308146-E38AB6CF-9F0B-4BD0-8BEE-FEAEDF846B3C Q27320038-F6651D60-A199-46A8-90E4-90A23BDB2A88 Q27329865-3F493CBE-335A-42E1-A980-DC0699A3BAF0 Q27500412-53019693-4513-4318-81EE-E537B5C6F40A Q28071398-6A78BE13-1D2D-4C42-82AB-59B5F98EB3A8 Q28077869-67E8C27B-1598-4EFA-80F1-82CC8885A3DB Q28081278-87A92A33-5BF7-41B4-A235-CACF54D1C071 Q28119005-7A528EE8-DAD0-484C-ABDF-D7FE31EFC2C6 Q28266387-637FCCCE-105E-405B-B6A9-069E975CF98A Q28282056-3056FD4B-3FD0-4C41-9094-E7487B43D9C1 Q30669674-B472AFCF-1ABE-4F97-A4C7-FD55DFB6B3C7 Q30805841-15C083A2-440C-4FAE-B7F0-949D6A95F1D5 Q31024674-DC702CB9-3DF7-40A4-B6AD-27800EA0F43C Q33640390-453A13E6-38D7-4AB8-8E41-23DAA662739B Q33926242-FB8E11C7-1375-49FA-BC54-74B02F8BB0CD Q34102829-BDAEB439-8E9D-404B-BE41-F7968DC4DC98 Q34205027-6345F906-07F7-4F8B-9835-6BC65464110C Q34562675-69E0C03E-1E97-4232-AD55-7F9E209319EB Q34664345-210117D0-6B55-4BA2-857A-441BC30342B6 Q34973787-E9C6C985-A354-48DF-BB8B-2A95D9FA1F2F Q34985153-5B625ACA-9BD7-43C5-BC79-0D20DD44C724 Q35008256-AFE1F83D-3768-4BED-8594-D3B84DABC071 Q35185595-8542E810-98B9-49E5-A69F-EA6A8740D80D Q35204878-476A122F-574B-4878-9D84-3EE0B683C9EE Q35216140-23C3D862-594A-4C29-8BF6-9A4766608971 Q35624263-5794882F-5DCE-4C00-AA44-56CE3D6C162D Q35636403-CB75F7F1-AE12-4A30-9800-ADB5E1E78340 Q35723422-7B3FDFCC-559E-4A2F-A632-368838F9FECA Q35745135-48F01ED2-1E05-4A64-844B-564BA965D3AD Q35826638-BBA5F307-73B3-4214-9874-3F2A7BFF252A Q35972860-FDEE8D23-C3D3-4AB8-AF12-480BAF1452B4 Q35986968-7716CCF2-0732-413C-8442-9DC82022E38F Q36003836-6F5A2414-06D5-4ED4-A437-3B72E941EE07 Q36005623-02AF5884-B5DF-4F36-8D54-734DD2FACEAD Q36240389-8992371D-F814-4FC8-BEE1-2AF15E9E9796 Q36286360-EA0040CB-7E04-4891-9962-DF7A21C115B0

P2860

Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model

http://www.wikidata.org/entity/Q35104249

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Immunotherapy targeting pathol ...... ne in a new tangle mouse model

@ast

Immunotherapy targeting pathol ...... ne in a new tangle mouse model

@en

type

label

Immunotherapy targeting pathol ...... ne in a new tangle mouse model

@ast

Immunotherapy targeting pathol ...... ne in a new tangle mouse model

@en

prefLabel

Immunotherapy targeting pathol ...... ne in a new tangle mouse model

@ast

Immunotherapy targeting pathol ...... ne in a new tangle mouse model

@en

P1433

Q35104249-AC39A304-CE8C-4E3C-A032-259009AFFE3A

P1476

Q35104249-EF988521-10C7-4C86-BB74-D75D763A4BDA

P2093

Q35104249-58784488-B24B-41A9-9660-FE209A1FD1B0

Q35104249-67CF6E20-6259-4C71-8291-4CBC44298FE5

Q35104249-892B4896-A9B4-486E-AD09-51FE02771810

P2860

Q35104249-016D46AA-4178-4018-88AF-2BC8CCD486EB

Q35104249-0958DE30-7F64-475F-8673-BB74144CDF93

Q35104249-0E2D81BA-FB5A-4B5C-8499-DD30114F309B

Q35104249-137CFE99-13E7-4071-9700-F5456A5EEFC4

Q35104249-141279BE-80AF-4F60-9AE5-4B4B674ACB99

Q35104249-1553F7F1-4914-43CB-AC43-BA4C828D0AD8

Q35104249-1E45077D-52DB-4B32-826F-E06E34891930

Q35104249-1EA3F220-9788-42F6-8260-B4AFDE000914

Q35104249-1F85162E-7B33-434B-B98F-4E1D84F4FAF8

Q35104249-20D6B158-A31C-45F2-908E-39094EA84BF8

P304

Q35104249-1C24A5D2-85D1-4BD1-83C3-9113DCF32C29

P31

Q35104249-34A6DA03-BCDF-4F03-9BA5-075F024005C4

P356

Q35104249-53C268E2-6F23-4000-8732-443F3D6FA5AC

P407

Q35104249-91DD3081-B232-4142-ACB0-A07F8620DCEE

P433

Q35104249-CD59A58B-32CE-4828-9441-84BE1A25C75C

P478

Q35104249-9AA383B0-8914-4655-9E4C-61DC3420DBC3

P577

Q35104249-DE0C7920-3742-439A-8774-A1F9C6171AAB

P698

Q35104249-274A2DF4-5560-4073-BD58-199C4A68EE2E

P921

Q35104249-33D4D4EB-819B-4ECA-9C7F-A474C2A87223

P932

Q35104249-B35AFA9D-6DCC-4CB4-8070-553C1ED70B67

P356

JNEUROSCI.4363-10.2010

P1433

Journal of Neuroscience

P1476

Immunotherapy targeting pathol ...... ne in a new tangle mouse model

@en

P2093

Allal Boutajangout

http://www.w3.org/2001/XMLSchema#string

David Quartermain

http://www.w3.org/2001/XMLSchema#string

Einar M Sigurdsson

http://www.w3.org/2001/XMLSchema#string

P2860

Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau

Transmission and spreading of tauopathy in transgenic mouse brain

Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing

Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model

Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1

Extracellular tau promotes intracellular calcium increase through M1 and M3 muscarinic receptors in neuronal cells

CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation

Alzheimer's presenilin 1 mutations impair kinesin-based axonal transport

PS1 activates PI3K thus inhibiting GSK-3 activity and tau overphosphorylation: effects of FAD mutations

Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins

P304

16559-16566

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1523/JNEUROSCI.4363-10.2010

http://www.w3.org/2001/XMLSchema#string

P407

P433

49

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2010-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21147995

http://www.w3.org/2001/XMLSchema#string

P921

P932

3135981

http://www.w3.org/2001/XMLSchema#string